Shamburg News · 8-K filed Nov 16, 2026, 4:05 PM EST

Acrivon Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

ACRV · Acrivon Therapeutics, Inc.

  • Earnings
  • Materiality: high

On November 16, 2026, Acrivon Therapeutics reported a net loss of $17.9 million for the quarter ended September 30, 2026, compared with $18.2 million a year earlier. Research and development expenses were $14.5 million and general and administrative expenses were $4.0 million for the quarter. The company reported cash, cash equivalents and investments of $77.8 million, expected to fund operations into the fourth quarter of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-463444.

Written from the filing by Shamburg Markets. Figures are as reported by the company.